CSF2 and neoplasm: In a pilot clinical study examining the safety and feasibility administering cyclophosphamide 7 days prior combined treatment with GM-CSF, pegylated IFN, and DCs loaded with autologous tumor lysate, cyclophosphamide pre-treatment increased levels of IL-12p70, NK cell cytotoxicity, and T cell reactivity to tumor antigens [194].